Cristal Therapeutics

What Cristal Therapeutics does

Cristal Therapeutics is a privately-held Dutch biotechnology company, founded in 2011 as a Utrecht University spin-off (originally Cristal Delivery B.V.) and headquartered in Maastricht, that builds and licenses three interconnected proprietary technology platforms: CliCr®, a copper-free click chemistry reagent based on TMTHSI that enables fast, site-specific bioconjugation without copper catalysis; CriPec®, a polymeric nanoparticle platform that transforms drug molecules into nanoparticles with negligible protein corona formation, enabling enhanced tumour accumulation and sustained drug release (clinically demonstrated at approximately 4-fold higher tumour uptake versus conventional docetaxel); and CriVac®, a vaccine platform that combines CriPec® nanoparticles with CliCr® conjugation to produce virus-mimicking coated nanoparticles that induce immune responses against displayed antigens. Its lead clinical asset, CPC634 (CriPec®-docetaxel), is in Phase 2 development for platinum-resistant ovarian cancer and other solid tumours, supported by a €2.5 million Horizon 2020 SME Instrument grant.

The company operates a licensing- and partnership-led business model rather than a commercial product sales model. Revenue is generated through technology licensing agreements (both exclusive and non-exclusive) for the CliCr®, CriPec®, and CriVac® platforms with pharmaceutical and biotech partners, supplemented by research and distribution arrangements. CliCr® reagents for non-GMP research are sold through Iris Biotech GmbH as authorized distributor; GMP applications and clinical-stage engagements are handled directly via the business development team. Strategic partners include Lonza (CliCr® embedded in its Bioconjugation Toolbox), Curapath (co-exclusive license for nucleic acid drug delivery), Sapreme Technologies (non-exclusive license), TBD Pharmatech (exclusive supply), Intravacc (COVID-19 vaccine collaboration), and iTeos Therapeutics (immuno-oncology). To date the company has raised over €20 million in equity financing from Thuja Capital, BioGeneration Ventures, Chemelot Ventures, Aglaia BioMedical Ventures, DROIA Oncology Ventures, and regional Dutch/Belgian funds, complemented by European Commission grants.

The company is small (1–10 employees) and is led by CEO/CMO Dr. Axel Mescheder (appointed November 2018, formerly of Pfizer, MSD, MediGene, and TopoTarget), Founder/CSO Dr. Cristianne Rijcken, CFO Andre Verwei (appointed 2019), CBO Jeroen Tonnaer, and Board Chairman Dr. Werner Cautreels (former CEO of Selecta Biosciences). The current strategic emphasis, evidenced by a cluster of 2023–2025 CliCr®-focused partnerships, has shifted from internal clinical development of CPC634 toward broader out-licensing of the CliCr® platform into bioconjugation, peptide synthesis, nucleic acid delivery, and gene-editing applications.

Name

Cristal Therapeutics

Legal name

Cristal Therapeutics

Website

https://cristaltherapeutics.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Cristal Therapeutics is a Dutch clinical-stage biotech that develops and licenses three proprietary platforms — CliCr® copper-free click chemistry, CriPec® polymeric nanomedicines, and CriVac® vaccines — serving pharmaceutical and biotech partners developing cancer therapeutics, bioconjugates, and gene-editing delivery systems.

Ownership category

akta.pro rank

Headquarters

HQ city

Maastricht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Technology Licensing: Cristal Therapeutics licenses its proprietary technology platforms (CliCr, CriPec, CriVac) to pharmaceutical and biotech partners under license agreements for various diagnostic and therapeutic applications. The company offers both exclusive and non-exclusive licensing arrangements.
2. Research Grants: The company has secured significant grant funding from European programs including Horizon 2020 SME Instrument grants (€2.5 million) and INNOSUP grants to support clinical development and platform advancement.
3. Equity Financing: Private company that has raised over €20M in equity financing from venture capital investors including Thuja Capital, BioGeneration Ventures, Aglaia BioMedical Ventures, DROIA Oncology Ventures, and others.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Cristal Therapeutics develops and licenses proprietary nanomedicine platforms for therapeutic and diagnostic applications. The company offers three interconnected technology platforms — CliCr® (copper-free click chemistry reagents), CriPec® (polymeric nanoparticle drug delivery), and CriVac® (vaccine technology) — licensed to pharmaceutical and biotech partners. Its lead clinical candidate CPC634 combines CriPec® nanoparticles with docetaxel and is in Phase 2 development for platinum-resistant ovarian cancer.

Product overview

Cristal Therapeutics is a clinical-stage pharmaceutical company offering three interconnected proprietary technology platforms: CliCr® (copper-free click chemistry reagent), CriPec® (polymeric nanoparticle drug delivery platform), and CriVac® (vaccine technology platform). These platforms work together to improve therapeutic profiles through superior conjugation (CliCr®), enhanced target specificity (CriPec®), and selective immune responses (CriVac®). The lead product candidate CPC634 combines CriPec® nanoparticles with docetaxel for cancer treatment. The company licenses these technologies under various agreement types and also commercializes CliCr® reagents through distribution partners.

Differentiator

Problem solved

Functional benefit

Brands

• CliCr®: Proprietary copper-free click chemistry reagent technology platform enabling efficient, site-specific and stable conjugation of biomolecules for therapeutic and diagnostic applications.
• CriPec®
• CriVac®
• CPC634

Products and services

• CliCr® Copper-Free Click Chemistry Reagent Proprietary copper-free click chemistry reagent platform based on TMTHSI (tetramethyl tetrahydroisoquinoline) that enables site-specific, stable, and fast conjugation of small molecules, biologics, nanoparticles, and other moieties via strain-promoted azide-alkyne cycloaddition, licensed to partners for therapeutic and diagnostic applications.
• CriPec® Polymeric Nanoparticle Drug Delivery Platform Polymeric nanoparticle technology platform that transforms drug molecules into customized nanoparticles via self-assembly, providing enhanced tumor accumulation, negligible protein corona formation, sustained drug release at target sites, and improved therapeutic profiles for cancer and other diseases, licensed to pharmaceutical partners.
• CriVac® Vaccine Technology Platform Proprietary vaccine technology platform combining biodegradable CriPec® nanoparticles with CliCr® conjugation chemistry for fast and controlled antigen conjugation, generating virus-mimicking coated nanoparticles that induce potent immune responses safely against displayed antigens, applicable for vaccine development.
• CPC634 (CriPec®-Docetaxel) Lead clinical-stage nanomedicine candidate combining CriPec® nanoparticles with entrapped docetaxel (Taxotere®) for treatment of platinum-resistant ovarian cancer and solid tumors, designed to enable enhanced tumor accumulation and localized drug release.

Quantifiable outcome

• 4-fold higher tumour accumulation of CriPec-docetaxel compared to conventional Taxotere in clinical studies
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• CurapathcoreOEM/ Whitelabel/ Licensing Partner · 26 November 2025Co-exclusive license agreement for CliCr bioconjugation platform. Curapath serves as exclusive CDMO to apply CliCr for delivery of nucleic acids via targeted polymeric and lipid nanoparticles (LNPs). Both parties have right to grant sublicenses in nucleic acid drug delivery field.
• TBD PharmatechcoreImplementation/ SI/ Consulting Partner · 23 September 2025Exclusive supply agreement where TBD Pharmatech serves as sole supplier of CliR conjugation reagents. Partnership leverages TBD Pharmatech's GMP manufacturing expertise and quality assurance for reliable, scalable production of CliCr to support Cristal Therapeutics' initiatives.
• Sapreme TechnologiescoreOEM/ Whitelabel/ Licensing Partner · 11 September 2025Non-exclusive license agreement allowing Sapreme Technologies to leverage CliCr platform in development of next-generation therapeutics based on their endosomal escape technology. Integration with CliCr enables accelerated pipeline development with robust manufacturing strategy.
• Iris Biotech GmbHcoreChannel Partner/ Reseller/ Distributor · 25 January 2023Iris Biotech sells CliCr and CliCr reagents for non-GMP research purposes as authorized distributor. For GMP applications, customers connect directly with Cristal Therapeutics.
• LonzacoreStrategic or Co-development Partner · 17 January 2023Cristal Therapeutics collaborates with Lonza on CliCr technology. CliCr is offered as part of Lonza's Bioconjugation Toolbox and Early Development Service offering. Lonza supports the entire product lifecycle from drug discovery through commercial manufacturing. The collaboration extends the impact of CliCr for use in bioconjugation applications in therapeutic and diagnostic products.
• IntravacccoreStrategic or Co-development Partner · 6 January 2021Strategic collaboration to develop novel vaccine programs against human diseases with initial focus on COVID-19. Cristal provides CliCr and CriVac technology; Intravacc provides OMV technology and detoxified LPS technology. First joint CriVac vaccine candidate targets receptor-binding domain of SARS-CoV-2.
• iTeos TherapeuticscoreStrategic or Co-development Partner · 6 December 2016Strategic partnership for development of immuno-oncology therapeutic candidates using CriPec nanotech platform. Initial goal to determine efficacy of iTeos immuno-oncology drug candidates in preclinical models. Option for iTeos to license Cristal's platform for up to three immune tumor-targeting programs.
• PX BiosolutionsminorStrategic or Co-development Partner · 14 July 2015Collaboration focused on application of CriVac vaccine technology for design of innovative vaccines. PX Biosolutions' DCtag vaccine formulations combined with Cristal's CriVac technology for enhanced vaccine platform flexibility.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Cartesian Therapeutics (formerly Selecta Biosciences): Clinical-stage biotech developing nanoparticle-based immunomodulatory therapies (ImmTOR, Treg therapies). Directly comparable as a nanoparticle platform company with both therapeutics and vaccine applications, overlapping with both CriPec and CriVac.
• Heidelberg Pharma: German biotech developing antibody-drug conjugates based on proprietary amanitin payload and linker chemistry. Directly comparable as a bioconjugation platform company with a similar licensing-focused business model overlapping with CliCr chemistry applications.
• NBE Therapeutics: Swiss biotech (now part of Boehringer Ingelheim) that developed site-specific antibody-drug conjugates using enzymatic conjugation chemistry. Directly comparable to Cristal as a bioconjugation platform company targeting ADCs and related modalities.
• Starpharma: Australian-listed biotech developing dendrimer-based nanoparticle drug delivery (DEP platform) with applications in oncology and infectious disease. Direct peer as a clinical-stage nanomedicine platform company with both internal products and licensing deals.
• NanoCarrier: Japanese clinical-stage biotech developing polymeric micelle nanoparticle drug delivery systems (e.g., NC-6004, NC-6300) for oncology. Direct peer in the polymeric nanoparticle drug delivery space, comparable in stage, mechanism, and oncology focus to CriPec.
• Vivesto (formerly Oasmia Pharmaceutical): Swedish nanomedicine company developing proprietary nanoparticle formulations of chemotherapeutics (e.g., Apealea/paclitaxel). Direct peer as a nanoparticle reformulation company targeting oncology indications with improved tolerability profiles.
• CytImmune Sciences: Clinical-stage biotech developing tumor-targeted gold nanoparticle therapeutics (Aurimune, CYT-6091) combining delivery and immunotherapy. Direct peer in oncology-focused nanoparticle drug delivery and a comparable platform-based licensing model.
• Arcturus Therapeutics: Clinical-stage biotech developing lipid nanoparticle (LNP)-enabled RNA medicines, including partnered COVID-19 and influenza vaccines. Directly comparable as an LNP delivery platform company with applications in both therapeutics and vaccines, overlapping with CriPec and CriVac.

Emerging players

• Sapreme Technologies: Dutch preclinical biotech developing endosomal escape technology to enhance intracellular delivery of therapeutics (ADCs, oligonucleotides). Comparable as a recently-signed CliCr licensee and a delivery-technology peer adjacent to CliCr-enabled bioconjugation.
• Curapath: Spanish CDMO specializing in polymer and lipid-based drug delivery systems (LNPs, polymeric nanoparticles). Co-exclusive CliCr licensee for nucleic acid delivery via LNPs; comparable as an emerging delivery-tech peer adjacent to both CliCr and CriPec applications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cristaltherap
• LinkedInlinkedin.com/company/cristal-delivery-bv

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cristal Therapeutics